Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
IFRX Catalyst Timeline
Dated clinical, regulatory and corporate events for InflaRx N.V.
Catalyst Timeline
Dated clinical, regulatory & corporate events for InflaRx N.V.
Upcoming catalysts 2
Event history 50
Past FDA Catalysts and PDUFA Decisions
How IFRX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-22 | izicopan | Pre-clinical data presentation | Pre-clinical |
Drug Pipeline Intelligence
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| IFX-1 BiologicsCompletedNCT04333420 | Severe COVID-19 Pneumonia | Phase 2/3 | COMPLETED | 399 | Dec 1, 2021 | ||||||
| IFX-1 BiologicsCompletedNCT03487276 | Hidradenitis Suppurativa | Phase 2 | COMPLETED | 191 | Jan 27, 2020 |
Clinical Trial Results
Readouts, endpoints and source filings for every IFRX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| izicopan | immune-inflammatory diseases | Phase 1 | 2026-11-06 | Izicopan achieved rapid and sustained inhibition of C5a/C5aR1 signaling; single doses ranging from 3 mg to 240 mg and at multiple doses of 30 mg once daily, 30 mg twice daily and 90 mg twice daily for 14 days; greater than 90% blockade of C5a-induced CD11b upregulation within two to four hours; strong activity maintained at 24 hours across most of the evaluated dose cohorts; greater than 90% blockade was observed following a single 30 mg dose; blockade exceeded 95% at multiple time points from Day 2 through Day 15; maximum plasma concentrations reached approximately 3.5 to 6 hours after dosingRead More | InflaRx Announces Publication of Phase 1 Data Demonstrating Favorable Safety and Pharmacokinetic/Pharmacodynamic Profile of IzicopanRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| No insider trades match the selected filters. | |||||
Hedge Fund 13F Activity
Hedge Funds invested in IFRX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TCG Crossover Management, LLC | 0.7 % (-12.5 %) | 26.10 M | 14.50 M |
Ownership Trends
IFRX Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How IFRX ranks across every disease it competes in
IFRX News
InflaRx Announces Publication of Phase 1 Data Demonstrating Favorable Safety and Pharmacokinetic/Pharmacodynamic Profile of Izicopan
InflaRx published Phase 1 data for izicopan, demonstrating its safety and pharmacokinetic profile. The study involved 86 healthy participants and showed favorable results, including rapid inhibition of C5a signaling. The findings support advancing izicopan into Phase 2 trials for immune-inflammatory diseases.
Read more →InflaRx Highlights Izicopan Development Path and Commercial Opportunity in ANCA-Associated Vasculitis at Capital Markets Day
InflaRx outlined its development strategy for izicopan at its Capital Markets Day, announcing plans for two Phase 2 trials in ANCA-associated vasculitis starting in 2027. The company anticipates significant market potential for izicopan, estimating peak sales between $1.5 billion and $2.0 billion. Initial data from related studies is expected in 2028.
Read more →InflaRx Announces November Investor Events
InflaRx N.V. announced its November investor events calendar, including participation in the Guggenheim Securities Healthcare Innovation Conference and the Jefferies Global Healthcare Conference. The company will report its third quarter 2026 financial results on November 3, 2026, via a Form 6-K with the SEC. Additionally, InflaRx will host a virtual Capital Markets Day on November 3 to discuss its development strategy for izicopan in ANCA-associated vasculitis.
Read more →InflaRx Highlights Izicopan’s Therapeutic Potential at Kidney Week 2026
InflaRx presented pre-clinical data on izicopan at Kidney Week 2026, showing renal protection in kidney disease models. Oral izicopan significantly reduced creatinine, blood urea nitrogen, and histopathological scores in hamster models. The company plans to advance the drug for ANCA-associated vasculitis and additional renal indications.
Read more →InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026
InflaRx N.V. has been selected to present late-breaking pre-clinical data on izicopan at Kidney Week 2026. The poster will highlight izicopan's potential as a second-generation oral C5a receptor antagonist in kidney disease models. The drug has demonstrated a favorable safety profile and significant therapeutic effects in various clinical studies.
Read more →InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development
InflaRx N.V. has appointed Dr. Gabriela Alperovich as Senior Vice President & Global Head of Clinical Development, effective October 1, 2026. Dr. Alperovich brings over 20 years of experience in the pharmaceutical industry, particularly in immune-inflammatory diseases. Her expertise will be crucial as InflaRx advances its lead program, izicopan, targeting renal and complement-driven diseases.
Read more →InflaRx to Host Virtual Capital Markets Day
InflaRx N.V. will host a virtual Capital Markets Event on November 3, 2026, featuring discussions on ANCA-associated vasculitis and the company's drug izicopan. Key opinion leaders will provide insights into the treatment landscape and the drug's potential advantages. The event aims to update stakeholders on InflaRx's clinical development strategy.
Read more →InflaRx Announces Participation in September Investor Conferences
InflaRx N.V. will participate in two investor conferences in September 2026, including the Cantor Global Healthcare Conference and the H.C. Wainwright Annual Global Investment Conference. The company will conduct fireside chats and one-on-one investor meetings at both events. InflaRx is known for its innovative anti-inflammatory therapeutics, particularly its lead program, izicopan.
Read more →InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones
InflaRx N.V. reported its second-quarter results for 2026, highlighting significant progress in the development of izicopan for ANCA-associated vasculitis and renal diseases. The company has a solid financial footing with €158.4 million in cash and plans to initiate a PK bridging study in China. A Capital Markets Day is scheduled for October 8, 2026, to discuss future strategies.
Read more →InflaRx to Report Second Quarter 2026 Results on August 6, 2026
InflaRx N.V. has announced it will report its second quarter 2026 financial results on August 6, 2026, prior to market opening. The company focuses on developing anti-inflammatory therapeutics, with its lead program izicopan showing promising results in clinical studies. No conference call is scheduled for this announcement.
Read more →InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos
InflaRx is evaluating a broader strategy for ANCA-associated vasculitis (AAV) in Europe following an EMA recommendation to revoke Tavneos' marketing authorization. The company plans to engage with the EMA regarding its anti-C5a antibody vilobelimab and the oral C5aR inhibitor izicopan. Despite regulatory challenges, Phase 2 planning with izicopan continues as scheduled.
Read more →InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares
InflaRx N.V. has completed an underwritten offering of 75 million ordinary shares at $2.00 each, raising $150 million. The proceeds will be utilized to further develop its pipeline and for general corporate needs. The offering saw participation from various investors, including prominent healthcare funds. Guggenheim Securities led the offering.
Read more →InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares
InflaRx N.V. has announced the pricing of its underwritten offering of 75 million ordinary shares at $2.00 each, aiming to raise $150 million. The proceeds will be utilized for advancing pipeline activities and general corporate purposes. The offering is set to close on May 7, 2026, pending customary conditions.
Read more →InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases
InflaRx N.V. is advancing izicopan, an oral C5a receptor inhibitor, for ANCA-associated vasculitis and other renal diseases. The company plans to conduct Phase 2 studies and aims to establish proof of concept in additional life-threatening kidney disorders. A Capital Markets Day is scheduled for summer 2026 to discuss izicopan's potential. InflaRx has sufficient funding to support its development programs through 2029.
Read more →InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes
InflaRx announced favorable pre-clinical data for izicopan, showing low reactive metabolite formation in human liver microsomes. This suggests a lower bioactivation-related safety risk compared to avacopan, a marketed C5aR1 inhibitor. The results support izicopan's potential for improved efficacy and safety in treating inflammatory diseases. The company aims to further validate these findings in clinical studies.
Read more →InflaRx to Report First Quarter 2026 Results on May 7, 2026
InflaRx N.V. will release its financial results for Q1 2026 on May 7, 2026, prior to market opening. The company is known for its innovative anti-inflammatory therapeutics targeting the complement system, particularly through its lead program izicopan. No conference call is scheduled for this announcement.
Read more →InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
InflaRx N.V. has announced that it has regained compliance with Nasdaq's minimum bid price requirement. The company achieved this by maintaining a closing bid price of $1.00 or greater for 10 consecutive business days. This compliance is crucial for the company's continued listing on Nasdaq and reflects positively on its market performance.
Read more →This is a translation into English of the deed of amendment to the articles of association of a public limited liability company under Dutch law. In the event of a conflict between the English and Dutch texts, the Dutch
InflaRx N.V. has enacted a deed of amendment to its articles of association, as decided during a general meeting of shareholders in Amsterdam. The amendment involves particular changes to the company's structure and share capital, with a specific focus on adjusting nominal values. The changes are set to take effect upon the issued share capital reaching a stipulated amount. This amendment follows a previous adjustment made in April 2025.
Read more →InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor
InflaRx N.V. has reported new in vitro data indicating that izicopan, an oral C5a receptor inhibitor, does not cause time-dependent inhibition of CYP3A4, which is crucial for assessing drug-drug interactions. This finding supports izicopan's potential as a best-in-class treatment for inflammatory diseases. The drug has demonstrated favorable pharmacokinetic and pharmacodynamic profiles in clinical studies.
Read more →CONVENING NOTICE This is the convening notice for the 2026 annual general meeting of shareholders of InflaRx N.V. (the " Company ") to be held on
InflaRx N.V. has issued a convening notice for its 2026 annual general meeting scheduled for April 23, 2026, in Amsterdam. The agenda includes the adoption of the annual accounts for 2025, reappointments of key executives, and auditor nomination. The company has also reiterated its policy of not paying dividends in the foreseeable future, focusing instead on retaining funds for business development. Shareholders must follow specific protocols to attend or vote at the AGM.
Read more →